Volume | 8,213 |
|
|||||
News | - | ||||||
Day High | 25.58 | Low High |
|||||
Day Low | 24.60 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
XOMA Corporation | XOMA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
25.58 | 24.60 | 25.58 | 24.78 | 25.44 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
450 | 8,213 | $ 25.23 | $ 207,245 | - | 13.48 - 27.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:01:52 | priorref | 262 | $ 24.78 | USD |
XOMA Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
286M | 11.63M | - | 4.76M | -40.83M | -3.51 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
XOMA News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XOMA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 25.08 | 26.735 | 24.60 | 25.74 | 11,100 | -0.30 | -1.20% |
1 Month | 25.67 | 26.79 | 24.00 | 25.48 | 11,101 | -0.89 | -3.47% |
3 Months | 20.18 | 27.00 | 19.50 | 24.65 | 18,152 | 4.60 | 22.79% |
6 Months | 19.20 | 27.00 | 14.27 | 20.53 | 22,795 | 5.58 | 29.06% |
1 Year | 18.45 | 27.00 | 13.48 | 18.59 | 29,834 | 6.33 | 34.31% |
3 Years | 38.01 | 39.02 | 13.48 | 21.40 | 30,113 | -13.23 | -34.81% |
5 Years | 12.51 | 46.32 | 12.47 | 23.25 | 39,263 | 12.27 | 98.08% |
XOMA Description
XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. |